Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives.
Clin Exp Gastroenterol. 2021 Aug 24;14:333-342. doi: 10.2147/CEG.S293272. eCollection 2021.
Clin Exp Gastroenterol. 2021.
PMID: 34466013
Free PMC article.
Review.
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
EMPA-KIDNEY Collaborative Group.
EMPA-KIDNEY Collaborative Group.
Lancet Diabetes Endocrinol. 2024 Jan;12(1):39-50. doi: 10.1016/S2213-8587(23)00321-2. Epub 2023 Dec 4.
Lancet Diabetes Endocrinol. 2024.
PMID: 38061371
Free PMC article.
Clinical Trial.
Item in Clipboard
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
EMPA-KIDNEY Collaborative Group.
EMPA-KIDNEY Collaborative Group.
Lancet Diabetes Endocrinol. 2024 Jan;12(1):51-60. doi: 10.1016/S2213-8587(23)00322-4. Epub 2023 Dec 4.
Lancet Diabetes Endocrinol. 2024.
PMID: 38061372
Free article.
Clinical Trial.
Item in Clipboard
Cite
Cite